Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals - Seite 2

• Released new and major improvements to existing technologies, including enabling the optimization of certain key ADMET properties, the first full release of technology to predict antibody affinity as a function of pH, software to more accurately predict small molecule pKa values, and a computational approach to identify brain penetrant molecules
• Published 21 peer-reviewed articles in life sciences and materials science journals

Business

• Appointed Margaret Dugan, M.D., as chief medical officer to lead clinical development and regulatory strategy for Schrödinger’s proprietary pipeline
• Strengthened balance sheet with $147.3M in cash distributions from Nimbus’s sale of its TYK2 inhibitor to Takeda
• Renewed and expanded battery research agreement with Gates Ventures for second three-year term
• Published inaugural corporate sustainability report

2024 Development and Operational Goals

Today Schrödinger outlined the following development and operational goals for 2024:

Development Goals

• Advance the Phase 1 study of SGR-1505 in advanced B cell malignancies to enable initial data release in late 2024 or 2025
• Advance the Phase 1 study of SGR-2921 in patients with AML/MDS to enable initial data release in late 2024 or 2025
• Submit the IND application for SGR-3515 in the first half of 2024 and initiate a Phase 1 study in 2024
• Advance the discovery-stage proprietary pipeline to enable an additional IND submission in 2025
• Present additional data from proprietary programs in one or more peer-reviewed forums
• Progress platform capabilities associated with biologics
• Publish research from the Gates battery research project building on existing publications

Operational Goals

• Drive continued scale up and adoption of Schrödinger’s software platform across life sciences and materials science industries
• Generate positive returns from strategic investments of Schrödinger’s technology, expertise and capital

Schrödinger will report its fourth quarter and full-year financial results and provide 2024 financial guidance on Wednesday, February 28, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.